Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study
BackgroundPituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether inf...
Main Authors: | Christina Deligianni, Lanfranco Pellesi, Basit Ali Chaudhry, Anne Luise Haulund Vollesen, Agneta Henriette Snoer, Jens Hannibal, Rigmor Højland Jensen, Messoud Ashina |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1135246/full |
Similar Items
-
PACAP38 in human models of primary headaches
by: Håkan Ashina, et al.
Published: (2017-11-01) -
Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
by: Lanfranco Pellesi, et al.
Published: (2022-04-01) -
PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism
by: John P. Vu, et al.
Published: (2023-07-01) -
Messenger RNA Gene Expression Screening of VIP and PACAP Neuropeptides and Their Endogenous Receptors in Ruminants
by: Emma Hawley, et al.
Published: (2022-10-01) -
PACAP and its role in primary headaches
by: Lars Edvinsson, et al.
Published: (2018-03-01)